New Enterprise Ventures is pleased to announce a new client relationship with Elucid to accelerate their AI software adoption in the life science market

Elucid is a Boston-based medical technology company using uniquely interpretable and validated AI to provide physicians with a cost-effective means to optimize treatment decisions for patients with known or suspected cardiovascular disease and drive diagnostic precision forward towards truly personalized medicine. The company’s software is the first FDA-Cleared and CE-marked non-invasive tool to quantify atherosclerotic plaque using histology, quantify Lipid Rich Necrotic Core, and determine plaque stability from CTA. It is also capable of deriving fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall and has recently demonstrated feasibility to estimate RNA expression from CTA. This unique set of information supports cost-effective therapeutic development on reduced timelines and informs better treatment decisions by physicians for cardiovascular disease.

Chris Cresswell, CEO of New Enterprise Ventures, commented,  “Elucid’s AI technology can non-invasively and cost-effectively measure cardiovascular therapeutic efficacy during clinical trials as well as enable optimization of patient inclusion/exclusion criteria.”

Dr. Philip Corcoran, added, “Elucid has successfully developed software which provides the ability to derive FFR calculations from standard CTA imaging and which uniquely identifies and accurately characterizes high risk atomic plaque features, enabling risk modeling to predict plaque biologic activity and adverse cardiovascular events, such as heart attack, stroke and ischemia. This software offers a non-invasive alternative to conventional catheter-based diagnostic procedures, while providing highly accurate atomic detail not previously possible.”